Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial

The Lancet

Volumn 386, Issue 9999, 2015, Pages 1156-1164

  Pritchard Jones, Kathy ^a   Bergeron, Christophe ^b   De Camargo, Beatriz ^c   Van Den Heuvel Eibrink, Marry M ^d   Acha, Tomas ^e   Godzinski, Jan ^f   Oldenburger, Foppe ^g   Boccon Gibod, Liliane ^h   Leuschner, Ivo ⁱ   Vujanic, Gordan ^j   Sandstedt, Bengt ^k   De Kraker, Jan ^g   Van Tinteren, Harm ^l   Graf, Norbert ^m  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b CENTRE LÉON BÉRARD   (France)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^d Department of Radiation Oncology   (Netherlands)

^e HOSPITAL MATERNO INFANTIL   (Spain)

^f T Marciniak Lower Silesia Specialist Hospital Wroclaw   (Poland)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^j CARDIFF UNIVERSITY   (United Kingdom)

^k KAROLINSKA INSTITUTE   (Sweden)

^l NETHERLANDS CANCER INSTITUTE   (Netherlands)

^m SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMEDIATE RISK PATIENT; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHRECTOMY; NEPHROBLASTOMA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOLESCENT; ADVERSE EFFECTS; CHILD; CLINICAL TRIAL; INFANT; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; PATHOLOGY; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME; WILMS TUMOR;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; DACTINOMYCIN; DOXORUBICIN; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEPHRECTOMY; TREATMENT OUTCOME; VINCRISTINE; WILMS TUMOR;

EID: 84942190861     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62395-3     Document Type: Article

References (33)

1. G Pastore, A Znaor, F Spreafico et al. Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project Eur J Cancer 42 2006 2103 2114
2. J de Kraker, N Graf, H van Tinteren et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial Lancet 364 2004 1229 1235
3. N Graf, H van Tinteren, C Bergeron et al. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01 Eur J Cancer 48 2012 3240 3248
4. DM Green, NE Breslow, JB Beckwith et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group J Clin Oncol 16 1998 3744 3751
5. K Pritchard-Jones, V Moroz, G Vujanic et al. Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial Ann Oncol 23 2012 2457 2463
6. PE Grundy, NE Breslow, S Li et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group J Clin Oncol 23 2005 7312 7321
7. GT Armstrong, KC Oeffinger, Y Chen et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer J Clin Oncol 31 2013 3673 3680
8. MM Geenen, MC Cardous-Ubbink, LC Kremer et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer JAMA 297 2007 2705 2715
9. AC Mertens, S Brand, KK Ness et al. Health and well-being in adolescent survivors of early childhood cancer: a report from the Childhood Cancer Survivor Study Psychooncology 23 2014 266 275
10. DM Green, YA Grigoriev, B Nan et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group J Clin Oncol 19 2001 1926 1934
11. HJ van der Pal, EC van Dalen, E van Delden et al. High risk of symptomatic cardiac events in childhood cancer survivors J Clin Oncol 30 2012 1429 1437
12. EC van Dalen, HJ van der Pal, HN Caron et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy Cochrane Database Syst Rev 4 2006 CD005008.
13. GM Vujanic, B Sandstedt, D Harms et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood Med Pediatr Oncol 38 2002 79 82
14. A Weirich, I Leuschner, D Harms et al. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH Ann Oncol 12 2001 311 319
15. H Reinhard, O Semler, D Burger et al. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor Klin Padiatr 216 2004 132 140
16. UK Clinical Research Network Study Portfolio The SIOP nephroblastoma clinical trial and study (WT2002-01) http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=1162 (accessed Dec 8, 2014).
17. C Mitchell, K Pritchard-Jones, R Shannon et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group Eur J Cancer 42 2006 2554 2562
18. MF Tournade, C Com-Nougue, J de Kraker et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the ninth International Society of Pediatric Oncology Wilms' Tumor trial and study J Clin Oncol 19 2001 488 500
19. MF Tournade, C Com-Nougue, PA Voute et al. Results of the sixth International Society of Pediatric Oncology Wilms' Tumor trial and study: a risk-adapted therapeutic approach in Wilms' tumor J Clin Oncol 11 1993 1014 1023
20. AC Verschuur, GM Vujanic, H Van Tinteren et al. Stromal and epithelial predominant Wilms tumours have an excellent outcome: the SIOP 93 01 experience Pediatr Blood Cancer 55 2010 233 238
21. C Rodary, C Com-Nougue, MF Tournade How to establish equivalence between treatments: a one-sided clinical trial in paediatric oncology Stat Med 8 1989 593 598
22. G Tunes da Silva, BR Logan, JP Klein Methods for equivalence and noninferiority testing Biol Blood Marrow Transplant 15 2009 120 127
23. D Machin, MJ Gardner Calculating confidence intervals for survival time analyses Br Med J (Clin Res Ed) 296 1988 1369 1371
24. EC van Dalen, MF Raphaël, HN Caron, LCM Kremer Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer Cochrane Database Syst Rev 19 2011 CD006647.
25. GJ D'Angio, N Breslow, JB Beckwith et al. Treatment of Wilms' tumor: results of the Third National Wilms' Tumor Study Cancer 64 1989 349 360
26. NE Breslow, SS Ou, JB Beckwith et al. Doxorubicin for favorable histology, stage II-III Wilms tumor: results from the National Wilms Tumor Studies Cancer 101 2004 1072 1080
27. DM Green, NE Breslow, GJ D'Angio et al. Outcome of patients with stage II/favorable histology Wilms tumor with and without local tumor spill: a report from the National Wilms Tumor Study Group Pediatr Blood Cancer 61 2014 134 139
28. C Fernandez Treatment of Wilms tumor in the Children's Oncology Group K Pritchard-Jones J Dome Renal tumors of childhood: biology and therapy 2014 Springer-Verlag Berlin 77 99
29. DM Green The treatment of stages I-IV favorable histology Wilms' tumor J Clin Oncol 22 2004 1366 1372
30. MM van den Heuvel-Eibrink, H van Tinteren, C Bergeron et al. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG) Eur J Cancer 51 2015 498 556
31. PE Grundy, DM Green, AC Dirks et al. Clinical significance of pulmonary nodules detected by CT and not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and 5: a report from the Children's Oncology Group Pediatr Blood Cancer 59 2012 631 635
32. J Wegert, N Ishaque, R Vardapour et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors Cancer Cell 27 2015 298 311
33. JG Blanco, CL Sun, W Landier et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes - a report from the Children's Oncology Group J Clin Oncol 30 2012 1415 1421